NR1H4 and diabetes mellitus: At present, a variety of FXR agonists have entered the clinical research stage worldwide, such as Obeticholic acid, EDP-305, Cilofexor, Tropifexor, LMB763, PXL007, etc. These drugs may show potential in the treatment of diabetes, but further clinical studies are needed to verify their efficacy and safety [117,118,119].